A series of previously unreported di- and triaryl(hetaryl)cyclopentenone derivatives were prepared using a convenient synthetic method and screened preliminarily for antitumor activity in four human cell lines, i.e., T-cell leukemia (Jurkat), lung adenocarcinoma (A-549), colon cancer (HCT-116), and breast adenocarcinoma (MCF-7). The most cytotoxic of the tested compounds was 2-(3,4,5-trimethoxyphenyl)-3-(4-methoxyphenyl) cyclopent-2-en-1-one. However, it was inactive against lymphocytic leukemia P388 in mice despite its cytotoxicity in in vitro tests.
This is a preview of subscription content,
to check access.References
B. Stewart and C. P. Wild (eds.), World Cancer Report 2014, WHO Press, (2014).
S. Nussbaumer, P. Bonnabry, J.-L. Veuthey, and S. Fleury-Souverain, Talanta, 85(5), 2265 – 2289 (2011).
R. H. Bradbury (ed.), “Cancer,” in: Topics in Medicinal Chemistry, Vol. 1, Springer-Verlag, Berlin, Heidelberg (2007).
J. H. Atkins and L. J. Gershell, Nat. Rev. Drug Discovery, 1(7), 491 – 492 (2002).
E. A. Perez, Mol. Cancer Ther., 8(8), 2086 – 2095 (2009).
C. Dumontet and M. A. Jordan, Nat. Rev. Drug Discovery, 9(10), 790 – 803 (2010).
C. Avendano and J. C. Menendez, Medicinal Chemistry of Anticancer Drugs, Chap. 8, (2008), p. 229.
G. C. Tron, T. Pirali, G. Sorba, et al, J. Med. Chem., 49(11), 3033 – 3044 (2006).
A. Nagle, W. Hur, and N. S. Gray, Curr. Drug Targets, 7(3), 305 – 306 (2006).
T. Brown, H. Holt, and M. Lee, Top. Heterocycl. Chem., 2, 1 (2006).
A. Cirla and J. Mann, Nat. Prod. Rep., 20(6), 558 – 564 (2003).
D. J. Chaplin, G. R. Pettit, C. S. Parkins, and A. S. Hill, Br. J. Cancer Suppl., 74, S86-S88 (1996).
G. Nagaiah and S. C. Remick, Future Oncol., 6(8), 1219 – 1228 (2010).
N.-H. Nam, Y. Kim, Y.-J. You, D.-H. Hong, et al., Bioorg. Med. Chem., 11, 1021 – 1029 (2003).
K. Oshumi, R. Nakagawa, Y. Fukuda, et al., J. Med. Chem., 41(16), 3022 – 3032 (1998).
K. Gaukroger, J. A. Hadfield, N. J. Lawrence, et al., Org. Biomol. Chem., 1, 3033 – 3037 (2003).
J. M. Andreu, B. Perez-Ramirez, M. J. Gorbunoff, et al., Biochemistry, 37(23), 8356 – 8368 (1998).
N.-H. Nam, Y. Kim, Y.-J. You, et al., Bioorg. Med. Chem. Lett., 12(15), 1955 – 1958 (2002).
M. K. Gurjar, R. D. Wakharkar, et al., USA Pat. Appl. No. 0229146 (2003); Chem. Abstr., 140, 16528 (2003).
M. K. Gurjar, R. D. Wakharkar, et al., Indian Pat. Appl. No. 2005DE00723 (2006); Chem. Abstr., 147, 406939 (2007).
G. R. Pettit, S. B. Singh, M. R. Boyd, et al, J. Med. Chem., 38(10), 1666 – 1672 (1995).
V. Z. Shirinian, A. A. Shimkin, D. V. Lonshakov, et al., J. Photochem. Photobiol., A, 233, 1 – 14 (2012).
V. Z. Shirinian, D. V. Lonshakov, A. G. Lvov, et al., Photochem. Photobiol. Sci., 12, 1717 – 1725 (2013).
V. Z. Shirinian, D. V. Lonshakov, V. V. Kachala, et al., J. Org. Chem., 77, 8112 – 8123 (2012).
A. A. Shimkin, V. Z. Shirinian, A. K. Mailian, et al., Russ. Chem. Bull., Int. Ed., 60(1), 139 – 142 (2011).
V. Z. Shirinian, A. G. Lvov, A. M. Yanina, et al., Chem. Heterocycl. Compd., 51(3), 234 – 241 (2015); Khim. Geterotsikl. Soedin., 51(3), 234 – 241 (2015).
D. V. Lonshakov, V. Z. Shirinian, and A. G. Lvov, Mendeleev Commun., 23, 268 – 270 (2013).
N.-H. Nam, Y. Kim, Y.-J. You, et al., Arch. Pharm. Res., 25(5), 600 – 607 (2002).
A. G. Lvov, V. Z. Shirinian, A. M. Kavun, Mendeleev Commun., 24, 277 – 279 (2014).
V. Z. Shirinian, A. G. Lvov, E. Yu. Bulich, et al., Tetrahedron Lett., 56, 5477 – 5480 (2015).
A. Van de Loosdrecht, R. H. J. Beelen, G. J. Ossenkoppele, et al., J. Immunol. Methods, 174, 311 – 320 (1994).
Methodical Recommendations for Preclinical Studies of Drug Antitumor Activity. Handbook for Preclinical Drug Trials [in Russian], Part 1, Grif i K, Moscow (2012), pp. 642 – 656.
Acknowledgments
The work was sponsored by the Russian Foundation for Basic Research (Grant 15 – 53 – 05049) and the Ministry of Education and Science of the Republic of Armenia (Grant 15RF-046) under collaborative science programs.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 51, No. 10, pp. 16 – 21, October, 2017.
Rights and permissions
About this article
Cite this article
Shirinyan, V.Z., Markosyan, A.I., Baryshnikova, M.A. et al. Synthesis and Antiproliferative Activity Evaluation of Aryl(Hetaryl)Cyclopentenone Analogs of Combretastatin A-4. Pharm Chem J 51, 867–872 (2018). https://doi.org/10.1007/s11094-018-1706-8
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11094-018-1706-8